Millennium Management’s Protalix BioTherapeutics PLX Stock Holding History

Millennium Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$400K	Buy	+171,535	New	+$363K	﹤0.01%	4936
2025 Q2	–	Sell	-963,011	Closed	-$2.47M	–	6229
2025 Q1	$2.47M	Buy	963,011 +575,090	+148%	+$1.37M	﹤0.01%	3581
2024 Q4	$729K	Buy	387,921 +14,164	+4%	+$20K	﹤0.01%	4453
2024 Q3	$381K	Sell	373,757 -437,403	-54%	-$460K	﹤0.01%	5036
2024 Q2	$949K	Buy	811,160 +800,676	+7,637%	+$946K	﹤0.01%	4144
2024 Q1	$13.2K	Buy	+10,484	New	+$15.7K	﹤0.01%	5881
2023 Q3	–	Sell	-21,232	Closed	-$42.5K	–	6455
2023 Q2	$42.5K	Sell	21,232 -65,466	-76%	-$156K	﹤0.01%	5505
2023 Q1	$182K	Buy	+86,698	New	+$152K	﹤0.01%	5209
2022 Q3	–	Sell	-19,223	Closed	-$21K	–	7396
2022 Q2	$21K	Buy	+19,223	New	+$22.5K	﹤0.01%	6474
2017 Q1	–	Sell	-11,010	Closed	-$49K	–	3768
2016 Q4	$49K	Buy	+11,010	New	+$49.2K	﹤0.01%	3254
2013 Q4	–	Sell	-3,439	Closed	-$156K	–	3706
2013 Q3	$156K	Buy	3,439 +1,734	+102%	+$89K	﹤0.01%	3147
2013 Q2	$84K	Buy	+1,705	New	+$90.5K	﹤0.01%	2881

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management's PLX Position: Q2 2026 in Review

Millennium Management opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 171,535 shares worth $400K. The stake represents ﹤0.01% of the portfolio and ranks #4936 among its holdings. This is a return to the name: Millennium Management previously reported a position in PLX as recently as Q1 2025.

Millennium Management first reported a position in PLX in Q2 2013 and has held it in 12 quarters since. The position peaked at $2.47M in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Millennium Management held 171,535 shares of Protalix BioTherapeutics worth $400K as of Q2 2026.
Protalix BioTherapeutics was a new Millennium Management position in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #4936 holding.
Millennium Management first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 12 quarters since.
Millennium Management's Protalix BioTherapeutics position peaked at $2.47M in Q1 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.